Certara has increased D360’s oligonucleotide research capabilities, while continuing to enhance its visualization features, workflows, and usability
PRINCETON, NJ – Aug. 15, 2018 – Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s world-class data access capabilities.
This latest release of Certara’s D360 self-service data informatics platform upgrades the efficiency and consistency of data-driven biologics research workflows for drug discovery scientists, adds a new multi-parameter scoring capability, and improves data analysis and visualization across all modalities.
With the advent of recombinant DNA technology and biomanufacturing, therapeutic discovery projects increasingly center on biologic modalities, especially oligonucleotides. The worldwide biologic drugs market is estimated to be valued at more than $200 billion, growing at a rate of 10% per year.1 While informatics systems for capturing biologics data are maturing, scientists often lack the tools required to understand and prioritize these entities efficiently, relying on manually-curated spreadsheets for crucial decision making.
“While many of our customers use D360 for biologics and small molecule research already, this latest release delivers discovery tools that significantly strengthen the platform’s oligonucleotide capabilities and workflows. We have also incorporated feedback from thousands of D360 users to fine-tune workflows and usability across modality types, allowing scientists to focus on the data and science instead of the software they are using,” said David Lowis, DPhil, senior director of D360 at Certara.
D360 v10.5’s new discovery research capabilities for biologics include:
- Oligonucleotide search by composition and similarity
- Oligonucleotide sequence rendering and formatting
- Oligonucleotide sequence filtering by composition and similarity
- Searching, filtering and rendering of HELM (Hierarchical Editing Language for Macromolecules)
In addition, D360 v10.5 features modality-independent, flexible, multi-parameter scoring that takes all relevant parameters into account and balances them against each other so that the best candidates can be identified quickly and consistently. Scientists can create, save, reuse, and share multi-parameter scoring functions that assess an array of multiple molecular properties to ensure efficacy, bioavailability and safety.
Certara also continues to enhance D360’s visualization features so that scientists can easily understand data’s meaning in a therapeutic context. The ability to visualize trends and their relationship to the compounds being tested allows more rapid understanding of structure activity relationships leading to improved decisions on project direction.
Employed by more than 5,000 scientists worldwide, D360 enables researchers to cut dramatically the time required to access and analyze data and gain new insights. Beyond the ability to ask and answer questions in real time, D360 allows users to create virtual compounds to analyze alongside those assays created in the laboratory.
To promote sharing of best practices and educate users about D360 v10.5, Certara is holding its D360 User Group Meeting on Oct. 9 and 10 in Dublin, Ireland. For more information, please contact email@example.com.
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence and knowledge integration. As a result, it optimizes R&D productivity, commercial value and patient outcomes. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Commercial Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions